# GET THE #1 PERIPHERAL STENT\* EVERFLEX™ STENT WITH ENTRUST™ DELIVERY SYSTEM

Simple. Predictable. Precise.


# **Trusted Performance**

You asked for simple deployment with reduced variability — and we delivered.


- 5 F low profile
- 0.035" guidewire compatibility
- Triaxial shaft design
- 150 cm catheter lengths

The EverFlex stent with Entrust delivery system offers the performance you've come to expect. The evidence is in the outcomes.

# PERCENT STENT FORESHORTENING



# **DEPLOYMENT DISTANCE FROM TARGET**



Test data on file at Medtronic. Results are not indicative of clinical performance.

### **REDESIGNED TIP**

Tip attached to outer catheter eliminates risk of tip catching the stent upon removal of delivery system

### **5 F DELIVERY SYSTEM**

Low profile may allow for:

- Smaller puncture site
- Less time applying pressure<sup>1</sup>
- Quicker ambulatory rates<sup>2</sup>
- Reduced vascular access complications<sup>3,4</sup>

### - 150 CM CATHETER LENGTH Long catheter allows for an extended reach

### TRIAXIAL DESIGN


Gold isolation sheath reduces friction from the system for increased accuracy and more predictable outcomes

### 0.035 IN GUIDEWIRE COMPATIBLE

Guidewire provides greater support for SFA procedures

### **EVERFLEX STENT**

- DURABILITY II study proves strong stent performance<sup>5,6</sup>
- Broad stent matrix minimizes need to place multiple stents
- Second-generation design for flexibility and durability in the SFA



Medtronic

# **EverFlex**<sup>™</sup> Self-expanding Peripheral Stent with **Entrust**<sup>™</sup> Delivery System

Catheter			Stent dimensions		Size compatibility		
<b>80 cm</b> Product catalog	<b>120 cm</b> Product catalog	<b>150 cm</b> Product catalog	Unconstrained stent diameter (mm)	Unconstrained stent length (mm)	Sheath/guide compatibility (F)	Guidewire acceptance (in)	Recommended vessel size (mm)
EVD35-06-020-080	EVD35-06-020-120	EVD35-06-020-150	6	20	5	0.035	4.5-5.5
EVD35-06-040-080	EVD35-06-040-120	EVD35-06-040-150	6	40	5	0.035	4.5-5.5
EVD35-06-060-080	EVD35-06-060-120	EVD35-06-060-150	6	60	5	0.035	4.5-5.5
EVD35-06-080-080	EVD35-06-080-120	EVD35-06-080-150	6	80	5	0.035	4.5-5.5
EVD35-06-100-080	EVD35-06-100-120	EVD35-06-100-150	6	100	5	0.035	4.5-5.5
EVD35-06-120-080	EVD35-06-120-120	EVD35-06-120-150	6	120	5	0.035	4.5-5.5
EVD35-06-150-080	EVD35-06-150-120	EVD35-06-150-150	6	150	5	0.035	4.5-5.5
EVD35-07-020-080	EVD35-07-020-120	EVD35-07-020-150	7	20	5	0.035	5.5-6.5
EVD35-07-040-080	EVD35-07-040-120	EVD35-07-040-150	7	40	5	0.035	5.5-6.5
EVD35-07-060-080	EVD35-07-060-120	EVD35-07-060-150	7	60	5	0.035	5.5-6.5
EVD35-07-080-080	EVD35-07-080-120	EVD35-07-080-150	7	80	5	0.035	5.5-6.5
EVD35-07-100-080	EVD35-07-100-120	EVD35-07-100-150	7	100	5	0.035	5.5-6.5
EVD35-07-120-080	EVD35-07-120-120	EVD35-07-120-150	7	120	5	0.035	5.5-6.5
EVD35-07-150-080	EVD35-07-150-120	EVD35-07-150-150	7	150	5	0.035	5.5-6.5
EVD35-08-020-080	EVD35-08-020-120	EVD35-08-020-150	8	20	5	0.035	6.5–7.5
EVD35-08-040-080	EVD35-08-040-120	EVD35-08-040-150	8	40	5	0.035	6.5-7.5
EVD35-08-060-080	EVD35-08-060-120	EVD35-08-060-150	8	60	5	0.035	6.5-7.5
EVD35-08-080-080	EVD35-08-080-120	EVD35-08-080-150	8	80	5	0.035	6.5-7.5
EVD35-08-100-080	EVD35-08-100-120	EVD35-08-100-150	8	100	5	0.035	6.5-7.5
EVD35-08-120-080	EVD35-08-120-120	EVD35-08-120-150	8	120	5	0.035	6.5-7.5
EVD35-08-150-080	EVD35-08-150-120	EVD35-08-150-150	8	150	5	0.035	6.5-7.5

### **Brief Statemen**

Indication: The EverFlex $^{\text{\tiny{M}}}$  Self-Expanding Peripheral Stent with Entrust $^{\text{\tiny{M}}}$  Delivery System is intended to improve luminal diameter in the treatment of symptomatic *de novo* or restenotic lesions up to 140 mm in length in the native Superficial Femoral Artery (SFA) and/or proximal popliteal arteries with reference vessel diameters ranging from 4.5–7.5 mm.

**Potential Adverse Events:** Potential adverse events that may be associated with the use of a stent in the SFA and proximal popliteal arteries include, but are not limited to: Allergic reaction, Amputation, Arterial dissection/perforation, Bleeding disorders (including GI, lymphatic), Infection (local or systemic including bacteremia or septicemia), Pseudoaneurysm, Restenosis, Stent/Vessel Thrombosis, and Surgical or endovascular intervention.

See the Instructions for Use provided with the product for a complete list of warnings, precautions, adverse events, and device information.

### $\hbox{\tt *EverFlex stent, U.S. only. DRG market share data for bare metal stents, November 2020.}$

- <sup>1</sup> Büchler JR, Ribeiro EE, Falcão JL, et al. A randomized trial of 5 versus 7 French guiding catheters for transfemoral percutaneous coronary stent implantation. *J Interv Cardiol.* February 2008;21(1):50-55.
- $^2$  Rodriguez A, Katz S. The use of the StarClose device for obtaining femoral artery hemostasis.  $\it Vasc Endovascular Surg.$  October 2011;45(7)627-630.
- <sup>3</sup> Meis A, Osada N, Schlegel PM, Fischbach R, Heindel W, Kloska SP. Sonographic follow-up of the access site after arterial angiography: Impact on the detected complication rate. *J Ultrasound Med*. September 2009;28(9):1151-1157.
- <sup>4</sup> Zahn R, Thoma S, Fromm E, et al. Do 5-F Catheters reduce the incidence of a pseudoaneurysm? *Int Angiol.* September 1996;15(5):257-260.
- <sup>5</sup> Rocha-Singh KJ, Bosiers M, Schultz G, et al. A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the Durability II trial. *Catheter Cardiovasc Interv.* July 2015;86(1):164-170.
- <sup>6</sup> Matsumura J. DURABILITY II 12-month data. Presented at ISET 2012: Miami, FL.

